Chimeric fusion proteins - Diphtheria toxin-based

A. E. Frankel, B. L. Powell, D. A. Vallera, Jr Neville D.M.

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Most cancer patients receive chemotherapy drugs that target DNA or the cell division apparatus. Many of these patients develop multidrug-resistant tumor cells, thus, novel methods to overcome drug resistance are needed. One approach is to target tumor cell protein synthesis. Peptide toxins, which catalytically inactivate protein synthesis, have been re-engineered to selectively bind and intoxicate tumor cells. Diphtheria toxin (DT), a member of the class of peptide toxins, has been subjected to structural and genetic analysis and protein engineering for several decades. In this review, we will examine the structure, function, synthesis and pharmacology of anticancer DT conjugates.

Original languageEnglish (US)
Pages (from-to)1294-1301
Number of pages8
JournalCurrent Opinion in Investigational Drugs
Volume2
Issue number9
StatePublished - 2001

Fingerprint

Diphtheria Toxin
Neoplasms
Proteins
Immunotoxins
Protein Engineering
Peptides
Drug Resistance
Cell Division
Pharmacology
Drug Therapy
DNA
Pharmaceutical Preparations

Keywords

  • Cell surface receptors
  • Diphtheria toxin
  • Fusion proteins
  • Immunotoxins
  • Receptor-mediated endocytosis
  • Toxin conjugates

ASJC Scopus subject areas

  • Pharmacology

Cite this

Frankel, A. E., Powell, B. L., Vallera, D. A., & Neville D.M., J. (2001). Chimeric fusion proteins - Diphtheria toxin-based. Current Opinion in Investigational Drugs, 2(9), 1294-1301.

Chimeric fusion proteins - Diphtheria toxin-based. / Frankel, A. E.; Powell, B. L.; Vallera, D. A.; Neville D.M., Jr.

In: Current Opinion in Investigational Drugs, Vol. 2, No. 9, 2001, p. 1294-1301.

Research output: Contribution to journalArticle

Frankel, AE, Powell, BL, Vallera, DA & Neville D.M., J 2001, 'Chimeric fusion proteins - Diphtheria toxin-based', Current Opinion in Investigational Drugs, vol. 2, no. 9, pp. 1294-1301.
Frankel, A. E. ; Powell, B. L. ; Vallera, D. A. ; Neville D.M., Jr. / Chimeric fusion proteins - Diphtheria toxin-based. In: Current Opinion in Investigational Drugs. 2001 ; Vol. 2, No. 9. pp. 1294-1301.
@article{9c8ceb3cb7534946be8fd8038370cb04,
title = "Chimeric fusion proteins - Diphtheria toxin-based",
abstract = "Most cancer patients receive chemotherapy drugs that target DNA or the cell division apparatus. Many of these patients develop multidrug-resistant tumor cells, thus, novel methods to overcome drug resistance are needed. One approach is to target tumor cell protein synthesis. Peptide toxins, which catalytically inactivate protein synthesis, have been re-engineered to selectively bind and intoxicate tumor cells. Diphtheria toxin (DT), a member of the class of peptide toxins, has been subjected to structural and genetic analysis and protein engineering for several decades. In this review, we will examine the structure, function, synthesis and pharmacology of anticancer DT conjugates.",
keywords = "Cell surface receptors, Diphtheria toxin, Fusion proteins, Immunotoxins, Receptor-mediated endocytosis, Toxin conjugates",
author = "Frankel, {A. E.} and Powell, {B. L.} and Vallera, {D. A.} and {Neville D.M.}, Jr",
year = "2001",
language = "English (US)",
volume = "2",
pages = "1294--1301",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Chimeric fusion proteins - Diphtheria toxin-based

AU - Frankel, A. E.

AU - Powell, B. L.

AU - Vallera, D. A.

AU - Neville D.M., Jr

PY - 2001

Y1 - 2001

N2 - Most cancer patients receive chemotherapy drugs that target DNA or the cell division apparatus. Many of these patients develop multidrug-resistant tumor cells, thus, novel methods to overcome drug resistance are needed. One approach is to target tumor cell protein synthesis. Peptide toxins, which catalytically inactivate protein synthesis, have been re-engineered to selectively bind and intoxicate tumor cells. Diphtheria toxin (DT), a member of the class of peptide toxins, has been subjected to structural and genetic analysis and protein engineering for several decades. In this review, we will examine the structure, function, synthesis and pharmacology of anticancer DT conjugates.

AB - Most cancer patients receive chemotherapy drugs that target DNA or the cell division apparatus. Many of these patients develop multidrug-resistant tumor cells, thus, novel methods to overcome drug resistance are needed. One approach is to target tumor cell protein synthesis. Peptide toxins, which catalytically inactivate protein synthesis, have been re-engineered to selectively bind and intoxicate tumor cells. Diphtheria toxin (DT), a member of the class of peptide toxins, has been subjected to structural and genetic analysis and protein engineering for several decades. In this review, we will examine the structure, function, synthesis and pharmacology of anticancer DT conjugates.

KW - Cell surface receptors

KW - Diphtheria toxin

KW - Fusion proteins

KW - Immunotoxins

KW - Receptor-mediated endocytosis

KW - Toxin conjugates

UR - http://www.scopus.com/inward/record.url?scp=0034835544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034835544&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 1294

EP - 1301

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 9

ER -